Westfield Capital Management Co. LP Sells 67,321 Shares of Insmed, Inc. $INSM

Westfield Capital Management Co. LP reduced its stake in Insmed, Inc. (NASDAQ:INSM) by 4.8% in the 2nd quarter, Holdings Channel reports. The firm owned 1,339,288 shares of the biopharmaceutical company’s stock after selling 67,321 shares during the period. Westfield Capital Management Co. LP’s holdings in Insmed were worth $134,786,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in INSM. Vanguard Group Inc. lifted its stake in shares of Insmed by 0.3% in the first quarter. Vanguard Group Inc. now owns 18,268,122 shares of the biopharmaceutical company’s stock worth $1,393,675,000 after buying an additional 49,149 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Insmed by 1.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,923,541 shares of the biopharmaceutical company’s stock worth $985,938,000 after acquiring an additional 219,131 shares during the period. Adage Capital Partners GP L.L.C. lifted its position in Insmed by 109.2% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 3,446,944 shares of the biopharmaceutical company’s stock worth $262,967,000 after acquiring an additional 1,799,382 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in Insmed by 3.0% during the second quarter. Artisan Partners Limited Partnership now owns 3,314,341 shares of the biopharmaceutical company’s stock valued at $333,555,000 after acquiring an additional 97,073 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Insmed by 2.5% in the first quarter. Alliancebernstein L.P. now owns 2,423,513 shares of the biopharmaceutical company’s stock valued at $184,890,000 after purchasing an additional 59,952 shares during the last quarter.

Insmed Stock Up 1.0%

INSM opened at $203.56 on Thursday. The company has a market capitalization of $43.41 billion, a P/E ratio of -35.65 and a beta of 1.05. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33. The firm’s fifty day moving average price is $165.61 and its two-hundred day moving average price is $123.38. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $205.11.

Insmed (NASDAQ:INSM) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. During the same quarter in the prior year, the company posted ($1.27) EPS. The company’s quarterly revenue was up 52.4% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on INSM. Bank of America increased their target price on Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Morgan Stanley upped their price target on Insmed from $126.00 to $144.00 and gave the stock an “equal weight” rating in a report on Thursday, August 21st. Jefferies Financial Group raised their price objective on shares of Insmed from $129.00 to $148.00 and gave the stock a “buy” rating in a research note on Wednesday, August 13th. UBS Group boosted their target price on shares of Insmed from $194.00 to $223.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Cowen reissued a “buy” rating on shares of Insmed in a report on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $173.29.

Insider Activity

In other Insmed news, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the sale, the director directly owned 262,675 shares of the company’s stock, valued at approximately $38,190,318.25. The trade was a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Elizabeth M. Anderson sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the completion of the sale, the director owned 63,729 shares in the company, valued at approximately $12,482,599.23. This represents a 13.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 252,922 shares of company stock valued at $43,533,383. 3.00% of the stock is owned by company insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.